健友股份 (603707)
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 161563.50
- Circulating A-Shares(W): 161563.50
- Earnings Per Share(RMB): 0.2700
- Net Assets Per Share(RMB): 4.1503
- Operating Revenue(W RMB): 292574.39
- Total Profit(W RMB): 46208.90
- **Net Profit Attributable to Parent(W RMB) **: 42946.72
- Net Profit Growth Rate(%): -29.11
- Weighted Return on Equity(%): 6.4700
- Operating Cash Flow Per Share(RMB): 0.5570
- Undistributed Profit Per Share(RMB): 2.4364
- Capital Reserve Per Share(RMB): 0.3635
2. Main Business
The main business covers:
- Research, development, production, and sales of pharmaceutical raw materials and preparations.
3. Company Basic Information
- Company Name: Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
- Listing Date: 2017-07-19
- Industry: Pharmaceutical Manufacturing
- Address: No. 16 Xuefu Road, Nanjing High-Tech Industrial Development Zone, Jiangsu Province
- Website: https://www.nkf-pharma.com
- Company Profile: Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. was established through the overall transformation of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. On February 27, 2011, Tang Yongqun, Xie Juhua, Huang Xiwei, and Coastal Group jointly signed the "Sponsor Agreement for the Overall Change of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. to Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.", deciding to transform King-Friend Limited into King-Friend Co., Ltd. According to the "Audit Report" issued by Tianheng Firm (Tianheng Audit No. (2011) 100), King-Friend Limited converted its net assets of 340,366,147.37 yuan as of January 31, 2011 into 120,000,000 shares, with a par value of 1 yuan per share, and the remaining 220,366,147.37 yuan was included in the capital reserve. On March 1, 2011, Tianheng Firm issued the "Capital Verification Report" (Tianheng Verification [2011] No. 015) for the company's establishment through overall change. On March 3, 2011, the company held its founding meeting. On March 8, 2011, the Nanjing Administration for Industry and Commerce issued the "Business License" (Registration No. 320191000010753) to King-Friend Co., Ltd.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Jiangsu Coastal Development Group Co., Ltd. | General Legal Person | 34416.50 | 21.30 |
| 2 | E Fund Management Co., Ltd. - China Life Insurance Company Limited - Participating Policy - E Fund China Life Shares Growth Equity Portfolio Single Asset Management Plan (Available for Sale) | Asset Management Plan | 1819.34 | 1.13 |
| 3 | Basic Pension Fund 1205 Portfolio | National Team | 1560.95 | 0.97 |
| 4 | E Fund Management Co., Ltd. - Social Security Fund 17042 Portfolio | National Team | 1297.29 | 0.80 |
| 5 | E Fund Quality Momentum Three-Year Holding Mixed Securities Investment Fund Class A | Public Fund | 1248.65 | 0.77 |
| 6 | Hong Kong Securities Clearing Company Limited | Northbound Capital | 948.61 | 0.59 |
| 7 | E Fund Kexiang Mixed Securities Investment Fund | Public Fund | 792.80 | 0.49 |
| 8 | Everbright Prudential Credit Tianyi Bond型 Securities Investment Fund Class A | Public Fund | 556.06 | 0.34 |
| 9 | Zheshang Zhixuan Pioneer One-Year Holding Mixed Securities Investment Fund Class A | Public Fund | 72.04 | 0.04 |
| 10 | Hengyue Medical Health Selected Mixed Securities Investment Fund Class A | Public Fund | 22.54 | 0.01 |
5. Concept Sectors
- Convertible Bonds
- Innovative Drugs
- Weight Loss Drugs
- Margin Trading & Securities Lending
- Share Buyback Plan
- Overseas Business
- Special Loans
- SSE 380
- Small-Cap Growth
- SZSE Growth
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information